Spotlight FCS for Health Care Professionals

FCS - Services

A lifelong low-fat diet is the cornerstone of FCS treatment. However, this is not easy to manage. In these cookbooks you can find tips on how to enjoy your meals while sticking to an FCS-friendly diet, as well as a variety of low-fat recipes. You can download these brochures here for free.

Materials

FCS cookbook

The FCS cookbook provides recipes suitable for the FCS diet, helping you make the dietary changes necessary to maintain optimal health.

Download as PDF

Nutritional brochure

Become more familiar with your body and learn what is good for you. This brochure is intended to be a guide to staying healthy, while still enjoying your meals.

Download as PDF

FCS patient brochure

This brochure provides important information about FCS and its impact on health.

Download as PDF

Orphanet

Although FCS is a very rare condition, new facts are continuously being discovered as more experience is gained in the field of fat metabolism. You can find more information about FCS at Orphanet.

More FCS info at Orphanet

Find an expert

As FCS is a very rare condition, diagnosis and treatment should be managed by an experienced doctor. Find a specialist near you at Orphanet.

Find your expert at Orphanet

References

  1. Nawaz H, et al. Elevated serum triglycerides are independently associated with persistent organ failure in acute pancreatitis. Am J Gastroenterol. 2015;110:1497-503.
  2. NCEPOD: Treat the cause. Avaliable at www.ncepod.org.uk/2016ap.html
  3. Valdivielso P, Ramírez-Bueno A, Ewald N. Current knowledge of hypertriglyceridemic pancreatitis. Eur J Intern Med. 2014 Oct;25(8):689-94.
  4. Rashid N, et al. Severe hypertriglyceridemia and factors associated with acute pancreatitis in an integrated health care system. J Clin Lipidol. 2016 Jul- Aug;10(4):880-890
  5. Moulin P, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an ”FCS score”. Atherosclerosis. 2018;275:265-72
  6. Gaudet D, et al. Targeting APOC3 in the Familial Chylomicronemia Syndrome. N Engl J Med. 2014;371:2200-6.
  7. Bashir B, et al. Severe Hypertriglyceridaemia and Chylomicronaemia Syndrome— Causes, Clinical Presentation, and Therapeutic Options. Metabolites. 2023; 13(5):621.
  8. Hegele et al. Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement Lancet Diabetes Endocrinol 2020; 8: 50–67
  9. Gaudet, et al. Targeting APOC3 in the Familial Chylomicronemia Syndrome. N Engl J Med. 2014;371 :2200–6.
  10. Gotoda T, et al. Diagnosis and management of type I and type V hyperlipoproteinemia J Atheroscler Thromb. 19: 1–12 (2012).
  11. Dron JS, Hegele RA. Genetics of Hypertriglyceridemia. Front Endocrinol (Lausanne). 24:11:455 (2020).
  12. Gan SI, et al. Hypertriglyceridemia-induced pancreatitis: A case-based review World J Gastroenterol 2006 November 28; 12(44): 7197-7202
  13. Davidson M, et al. The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study. J Clin Lipidol 2018;12(4):898–907.
  14. Gaudet D et al., Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency Atherosclerosis Supplements 11 (2010) 55–60
  15. Pedersen SB et al. Nonfasting Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis. JAMA Intern Med 2016;176:1834–42
  16. Baass A, et al. Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia (Review). J Intern Med 2020; 287: 340–348.
  17. Bashir et al. Atherosclerosis 391 (2024) 117476¸ https://doi.org/10.1016/j.atherosclerosis.2024.117476
  18. Laufs U, et al. Clinical review on triglycerides. European Heart Journal (2020) 41, 99–109.
  19. Brahm AJ, Hegele RA, Chylomicronemia and current diagnosis and future therapies, Nat. Rev. Endocrinol. 11 (6) (2015) 352e362.
  20. Pancreatitis Pain: Causes, Symptoms, Diagnosis, Treatment. Available at: www.ezmedlearning.com/blog/pancreatitis-causes-symptoms-diagnosis-treatment.
  21. Ginsberg HN, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 14;42(47):4791-4806 (2021).
  22. Williams L, et al. Familial chylomicronemia syndrome: Bringing to life dietary recommendations throughout the life span. J Clin Lipidol. 2018; 12:908–19.
  23. Burnett JR, Hooper AJ, Hegele RA. Familial Lipoprotein Lipase Deficiency. 1999 Oct 12 [Updated 2017 Jun 22]. In: Adam MP, Mirzaa GM, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1308/.
  24. Alexander L, et al. Familial chylomicronaemia Syndrome (FCS): Medical Nutrition Therapy for Patients and Providers. Presented at NLA Scientific Sessions; Philadelphia,PA; 17–20 May, 2017.
  25. Witzum JL, et al. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. N Eng J Med. 2019;381(6):531-42.

You are leaving the Spotlight FCS website

Please note that this third-party website is not controlled by Spotlight FCS or subject to our privacy policy.

Thank you for visiting Spotlight FCS. We hope you come back again soon.

Open